Spindle Cell Lipoma
Spindle cell lipoma (SCL) and its closely related variant, pleomorphic lipoma (PL), are relatively rare benign forms of lipoma, accounting for about 1.5% of all benign fatty tumors. They are made up of a mixture of mature fat cells, uniform spindle cells, thick birefringent rope-like collagen bundles and a myxoid (mucinous) background.
Clinically, the pattern is very distinctive: it occurs overwhelmingly in older men (male-to-female ratio about 9:1, ages 45–70) and classically develops on the back of the neck, the shoulders and the upper back. Because it contains spindle cells and, in the pleomorphic variant, multinucleated floret-like giant cells, it can easily be mistaken under the microscope for well-differentiated liposarcoma (WDLPS) or a spindle cell sarcoma. Without specific cytogenetic or immunohistochemical testing (CD34, MDM2), this can lead to overtreatment.
At Haute-Derma, we confirm the diagnosis with immunohistochemical markers (CD34/MDM2/Rb) and 3.0T MRI, then remove the tumor with its capsule intact using careful microsurgical dissection, giving patients complete removal of the lesion and an excellent outlook for recovery.
Clinical Background and Pathological Classification
Causes and Cytogenetics
- Characteristic genetic change (loss of the retinoblastoma gene, RB1):
- At the molecular level, spindle cell lipoma is defined by deletions of chromosome 13q14 or 16q, which lead to loss of expression of the RB1 tumor suppressor gene (retinoblastoma 1 protein).
- Loss of Rb protein (Rb-negative) on immunohistochemistry is a key biomarker that confirms the diagnosis of SCL.
- Distinctive epidemiology:
- Mainly affects men aged 45–70 (> 90% of cases).
- Strongly favored sites: the back of the neck (nuchal region), shoulder girdle and upper back. It rarely occurs on the legs or inside the abdomen.
Histopathology (the Gold Standard)
Under the microscope, SCL shows varying proportions of four core components:
- Mature adipocytes: Evenly distributed, without atypical nuclei or malignant lipoblasts.
- Uniform spindle cells:
- The spindle cells have olive-shaped or elongated nuclei with inconspicuous nucleoli, and mitoses are very rare (< 1 per 10 HPF).
- They are arranged in short bands or clusters between the fat cells.
- Rope-like collagen bundles: Thick, glassy, birefringent collagen bundles woven between the spindle cells.
- Myxoid stroma: A connective tissue background rich in mucopolysaccharides, with a moderate density of small blood vessels.
- Pleomorphic lipoma variant: Considered part of the same disease spectrum as SCL. In addition to the components above, it contains floret-like giant cells: multinucleated cells whose nuclei are arranged in a ring at the periphery like flower petals. Despite their unusual “pleomorphic” look, these cells are entirely benign.
Differential Diagnosis and Immunohistochemistry (IHC)
| Condition | Immunohistochemical Markers (IHC) | Distinguishing Microscopic Features |
|---|---|---|
| Spindle cell lipoma (SCL) | Strong CD34 (+); loss of Rb (Rb –); S100 (+) in fat cells; MDM2 (–); CDK4 (–) | Uniform spindle cells; rope-like collagen; floret-like cells (pleomorphic variant); no lipoblasts. |
| Well-differentiated liposarcoma (WDLPS) | Strong MDM2 (+); strong CDK4 (+); MDM2 gene amplification (+) on FISH; Rb (+) | Malignant lipoblasts with atypical hyperchromatic nuclei, irregular proliferation; usually deep in the legs or retroperitoneum. |
| Neurofibroma | Fibrillary S100 (+); sparse CD34 (+); Rb (+) | Wavy Schwann cells; no thick rope-like collagen bundles or floret-like cells. |
| Spindle cell leiomyoma | SMA (+); desmin (+); CD34 (–) | Spindle-shaped smooth muscle cells with cigar-shaped nuclei (perinuclear vacuoles on cross-section). |
Our Approach to Treating Spindle Cell Lipoma
Haute-Derma’s management of spindle cell lipoma rests on three principles: confirm the diagnosis with immunohistochemistry, remove the tumor completely with its capsule using microsurgical technique, and preserve function:
- Mandatory confirmation of CD34 (+), Rb (–) and MDM2 (–): This reliably excludes liposarcoma before treatment and spares patients unnecessarily extensive, destructive surgery.
- Complete encapsulated excision: Most SCLs have a well-defined fibrous capsule and sit superficially in the subcutaneous fat of the neck or shoulders, so careful microsurgical removal of the whole capsule usually cures the lesion with a very low recurrence rate.
- Cosmetic incisions hidden in the natural skin lines of the back and neck (Langer’s lines): For the best possible appearance of the neck and shoulder area.
Diagnosing Spindle Cell Lipoma at Haute-Derma
- Clinical examination and history: We assess the lump under the skin of the nape, shoulders or upper back in middle-aged or older men. It is usually soft to slightly firm, mobile, painless and slow-growing.
- 3.0T magnetic resonance imaging (MRI): Shows an encapsulated tumor of mixed signal, with fat signal (high on T1) interwoven with low-signal bands representing spindle cell fibrous tissue and myxoid material. MRI confirms that the tumor is confined to the subcutaneous layer and has not invaded the deep neck muscles.
- Core needle biopsy with mandatory IHC: H&E staining plus a marker panel of CD34, Rb, MDM2, CDK4 and S100 confirms the microscopic diagnosis.
Specialist Treatment at Haute-Derma
- Microsurgical removal of the tumor with its capsule (microsurgical enucleation/excision):
- Indication: The gold-standard treatment for spindle cell lipoma.
- Technique: A minimal incision is made along a skin crease of the nape or shoulder, and the fibrous capsule is meticulously separated from the healthy fat and the deep cervical fascia. Layered closure eliminates dead space and limits fluid collection.
- Cosmetic recovery and scar care for the neck and shoulders: He-Ne laser or LED light is used right after surgery to reduce swelling, followed by fractional CO2 laser once the stitches are out to leave a smooth scar that blends with the surrounding skin.
- Follow-up: A local ultrasound check at 6 months and 1 year. Because SCL is benign, no further systemic cancer surveillance is needed.
